Somatropin, a hormone that sends a message to the pituitary gland to stimulate growth in the human body, is not a new discovery. And its synthesis is not a new technological advance -- somatropin products have been on the market for more than a decade, protected by patents covering things like the way the hormone is made to how it is administered.
But the basic patent on the copy of the hormone produced naturally in most people has expired. And Sandoz, the generic drug division of the Swiss pharmaceutical giant Novartis, has applied for permission to market Omnitrop, its own somatropin copy, in Europe.
If it is approved as expected this fall, Omnitrop will be the first generic version of a genetically engineered medicine allowed to be sold in Europe. And the comfortable world of biotechnology may be violently shaken by losing its hold on an industry that has US$30 billion in annual global sales and is growing nearly 10 percent a year.
Though no generic version of genetically engineered drugs has been approved in the US, executives at Sandoz say they will soon ask the Food and Drug Administration for the right to market Omnitrop, probably early next year.
Until now, biotechnology companies have never thought it possible to make a generic version of their medicines because the molecules and the manufacturing process are so complex. Laws in the US and Europe that cover generics of traditional chemical drugs do not cover this new breed of medicines, often called biologics -- products made from living cells, blood factors and genetically engineered proteins.
But now, as the first patents on biologics are beginning to expire, pressure for updated laws is coming from generic drug makers wanting a piece of the pie and from patients and consumer groups hoping to cut the price of these products, which can cost more than US$100,000 a year.
Two months ago, the EU passed legislation allowing companies to apply for permission to sell generic versions of genetically engineered drugs. While regulators fine-tune the guidelines, generic biologics will be evaluated on an individual basis.
The EU's approval of Omnitrop, which has received support from an advisory committee, would make it more likely that the FDA would also allow generic competition for biologics, perhaps announcing rules as early as next year.
Patents galore
Biologics often carry multiple patents; a therapy can have 14 different patents, on everything from a particular cell line to the manufacturing process.
Most biologics will start to lose their patent protection and be open to competition beginning in 2005. But human growth hormones and a handful of other drugs using recombinant-gene technology are already off patent. They include insulin for diabetes, beta interferon for multiple sclerosis and alpha interferon for hepatitis and cancer. Together, they have annual global sales of US$13.5 billion.
Still, just a handful of generic drug makers have the expertise and other resources to develop, test and manufacture a comparable biologic, though the number may grow. Early on, at least, probably only the larger concerns with both biotechnology and generic expertise will be able to enter the generic market for biologics -- companies like Novartis, Teva Pharmaceutical Industries of Israel and the Merck Group of Germany.
A big unanswered question is whether generic biologics can be sold at the big discounts normally seen on other generic drugs, given the extraordinary expenses involved in a biologic's creation.
Generic versions of traditional chemical drugs can be approved for sale without lengthy, and expensive, clinical testing to show they are safe and effective, because the chemical processes can be standardized and the drugs copied easily. But with living things it is hard to verify sameness -- and prove that a product is as effective or safe.
These issues are now being pondered by regulators.
In considering Omnitrop's application, EU authorities required Sandoz to conduct clinical trials first on healthy volunteers to test for side effects and then on patients with a growth hormone deficiency to prove its safety and efficacy -- tests routinely required on any new drug.
But unlike the companies that developed the original drug, Sandoz did not have to show that the active ingredient, somatropin, was effective at treating growth deficiencies because that already has been proven.
Possible dangers
Scientists at two companies that currently sell somatropin products, Serono of Geneva and Genentech of California, say that generic biologics need to go through exactly the same testing as the original biologics.
Even the slightest change in a bioengineered product, they say, can elicit a different -- and sometimes harmful -- response. An example often pointed to is a bioengineered anemia medicine made under license by two different companies; one version had no serious side effects while the other did. No one has figured out why.
"On the patient health side, I have a lot of concern," Walter Moore, vice president for governmental affairs at Genentech, said in a telephone interview from his office in South San Francisco.
"The crux is, if the process defines the product, I don't see how we can skip any human clinical trials," he said.
Thomas Szucs, a professor at the European Center for Pharmaceutical Medicine at the University of Basel, agreed.
"Good manufacturing practice is basically becoming in biotechnology sometimes the even greater hurdle than the technology," Professor Szucs said.
"That's what I'm seeing now," he said. For example, human insulin no longer is protected by patents but has faced no generic competition because it is too hard to make, he said.
He is also skeptical that a large market for generic biologics will ever be developed because of the complexity of the molecules involved.
In the US, there are additional obstacles. Mark McClellan, the FDA commissioner since November, has said it will take federal legislation to establish a mechanism for approving generic biologics. And another FDA official said that even the definition of a biologic was under consideration.
Meantime, generic drug makers have been pushing to get comparable biologics approved through the Hatch-Waxman Act, a 1984 statute governing generic drugs.
But in April, the Biotechnology Industry Organization, a trade group based in Washington, petitioned the FDA to withdraw draft rules that would have allowed comparable biologics to be eligible for approval.
The agency is expected to conclude its examination of generic biologics by year's end.
The EU is working with authorities in the US and Japan to harmonize the approval processes for all drugs, so it is very likely that generic biologics in the US also will be decided case by case, one EU official said.
ROLLER-COASTER RIDE: More than five earthquakes ranging from magnitude 4.4 to 5.5 on the Richter scale shook eastern Taiwan in rapid succession yesterday afternoon Back-to-back weather fronts are forecast to hit Taiwan this week, resulting in rain across the nation in the coming days, the Central Weather Administration said yesterday, as it also warned residents in mountainous regions to be wary of landslides and rockfalls. As the first front approached, sporadic rainfall began in central and northern parts of Taiwan yesterday, the agency said, adding that rain is forecast to intensify in those regions today, while brief showers would also affect other parts of the nation. A second weather system is forecast to arrive on Thursday, bringing additional rain to the whole nation until Sunday, it
CONDITIONAL: The PRC imposes secret requirements that the funding it provides cannot be spent in states with diplomatic relations with Taiwan, Emma Reilly said China has been bribing UN officials to obtain “special benefits” and to block funding from countries that have diplomatic ties with Taiwan, a former UN employee told the British House of Commons on Tuesday. At a House of Commons Foreign Affairs Committee hearing into “international relations within the multilateral system,” former Office of the UN High Commissioner for Human Rights (OHCHR) employee Emma Reilly said in a written statement that “Beijing paid bribes to the two successive Presidents of the [UN] General Assembly” during the two-year negotiation of the Sustainable Development Goals. Another way China exercises influence within the UN Secretariat is
CHINA REACTS: The patrol and reconnaissance plane ‘transited the Taiwan Strait in international airspace,’ the 7th Fleet said, while Taipei said it saw nothing unusual The US 7th Fleet yesterday said that a US Navy P-8A Poseidon flew through the Taiwan Strait, a day after US and Chinese defense heads held their first talks since November 2022 in an effort to reduce regional tensions. The patrol and reconnaissance plane “transited the Taiwan Strait in international airspace,” the 7th Fleet said in a news release. “By operating within the Taiwan Strait in accordance with international law, the United States upholds the navigational rights and freedoms of all nations.” In a separate statement, the Ministry of National Defense said that it monitored nearby waters and airspace as the aircraft
Taiwan’s first drag queen to compete on the internationally acclaimed RuPaul’s Drag Race, Nymphia Wind (妮妃雅), was on Friday crowned the “Next Drag Superstar.” Dressed in a sparkling banana dress, Nymphia Wind swept onto the stage for the final, and stole the show. “Taiwan this is for you,” she said right after show host RuPaul announced her as the winner. “To those who feel like they don’t belong, just remember to live fearlessly and to live their truth,” she said on stage. One of the frontrunners for the past 15 episodes, the 28-year-old breezed through to the final after weeks of showcasing her unique